{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:16Z","timestamp":1793725696324,"version":"4.6.1"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40265-025-02263-0","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T15:56:04Z","timestamp":1765036564000},"page":"11-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2625-0273","authenticated-orcid":false,"given":"Setor K.","family":"Kunutsor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-7018","authenticated-orcid":false,"given":"Samuel","family":"Seidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"2263_CR1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-202-LB","author":"AB Kaiser","year":"2018","unstructured":"Kaiser AB, Zhang N, Der Pluijm WV. Global prevalence of type 2 diabetes over the next ten years (2018\u20132028). Diabetes. 2018. https:\/\/doi.org\/10.2337\/db18-202-LB.","journal-title":"Diabetes"},{"issue":"8","key":"2263_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","volume":"33","author":"T Seuring","year":"2015","unstructured":"Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811\u201331. https:\/\/doi.org\/10.1007\/s40273-015-0268-9.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"2263_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00125-022-05713-6","volume":"65","author":"J Liu","year":"2022","unstructured":"Liu J, Bai R, Chai Z, Cooper ME, Zimmet PZ, Zhang L. Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990\u20132019 data. Diabetologia. 2022;65(8):1339\u201352. https:\/\/doi.org\/10.1007\/s00125-022-05713-6.","journal-title":"Diabetologia"},{"issue":"1","key":"2263_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. 2024;9(1):262.","journal-title":"Signal Transduct Target Ther"},{"issue":"10085","key":"2263_CR5","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239\u201351.","journal-title":"Lancet"},{"issue":"Supple 1","key":"2263_CR6","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.2337\/dc23-S001","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 1. Improving care and promoting health in populations: standards of care in diabetes-2023. Diabetes Care. 2023;46(Supple 1):S10\u20138.","journal-title":"Diabetes Care"},{"key":"2263_CR7","unstructured":"World Health Organization. Obesity and overweight. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 09 July 2025 [cited]."},{"key":"2263_CR8","doi-asserted-by":"crossref","unstructured":"Collaborators GBDAB. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813\u201338.","DOI":"10.2139\/ssrn.5533924"},{"issue":"1","key":"2263_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2337\/cd21-0043","volume":"40","author":"IH Vieira","year":"2022","unstructured":"Vieira IH, Barros LM, Baptista CF, Rodrigues DM, Paiva IM. Recommendations for practical use of Metformin, a central pharmacological therapy in type 2 diabetes. Clin Diabetes. 2022;40(1):97\u2013107. https:\/\/doi.org\/10.2337\/cd21-0043.","journal-title":"Clin Diabetes"},{"key":"2263_CR10","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98\u2013110.","DOI":"10.2337\/dc20-S009"},{"issue":"4","key":"2263_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ihj.2020.07.009","volume":"72","author":"M John","year":"2020","unstructured":"John M, Kalra S, Nair T. Modern sulphonylureas and cardiovascular adverse effects: will CAROLINA put an end to the controversy? Indian Heart J. 2020;72(4):312\u20135.","journal-title":"Indian Heart J"},{"issue":"3","key":"2263_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/dom.12821","volume":"19","author":"S Bain","year":"2017","unstructured":"Bain S, Druyts E, Balijepalli C, Baxter CA, Currie CJ, Das R, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19(3):329\u201335. https:\/\/doi.org\/10.1111\/dom.12821.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2263_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/dom.12456","volume":"17","author":"AS Abdelmoneim","year":"2015","unstructured":"Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, et al. Cardiovascular safety of sulphonylureas: over 40\u00a0years of continuous controversy without an answer. Diabetes Obes Metab. 2015;17(6):523\u201332. https:\/\/doi.org\/10.1111\/dom.12456.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2263_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.12116","volume":"15","author":"M Monami","year":"2013","unstructured":"Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938\u201353. https:\/\/doi.org\/10.1111\/dom.12116.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2263_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u20139. https:\/\/doi.org\/10.1097\/MED.0000000000000311.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2263_CR16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73\u201385.","DOI":"10.2337\/dc18-S008"},{"key":"2263_CR17","doi-asserted-by":"crossref","unstructured":"Kunutsor SK, Zaccardi F, Balasubramanian VG, Gillies CL, Aroda VR, Seidu S, et al. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes Obes Metab. 2024;26(5):1837\u201349.","DOI":"10.1111\/dom.15500"},{"issue":"6","key":"2263_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.pcd.2024.09.007","volume":"18","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor SK, Seidu BS, Seidu S. Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials and real-world evidence. Prim Care Diabetes. 2024;18(6):589\u201398. https:\/\/doi.org\/10.1016\/j.pcd.2024.09.007.","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"2263_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/14017431.2024.2418086","volume":"58","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor SK, Seidu S, Dey RS, Baidoo IK, Oulhaj A. Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials. Scand Cardiovasc J. 2024;58(1):2418086. https:\/\/doi.org\/10.1080\/14017431.2024.2418086.","journal-title":"Scand Cardiovasc J"},{"issue":"5","key":"2263_CR20","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/dom.15500","volume":"26","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor SK, Zaccardi F, Balasubramanian VG, Gillies CL, Aroda VR, Seidu S, et al. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes Obes Metab. 2024;26(5):1837\u201349. https:\/\/doi.org\/10.1111\/dom.15500.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2263_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","journal-title":"Signal Transduct Target Ther"},{"issue":"9548","key":"2263_CR22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"issue":"11","key":"2263_CR23","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"},{"issue":"2","key":"2263_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","volume":"36","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Prevention of cardiorenal complications in people with type 2 diabetes and obesity. Cell Metab. 2024;36(2):338\u201353.","journal-title":"Cell Metab"},{"issue":"7","key":"2263_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"issue":"22","key":"2263_CR26","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1001\/jama.2023.24539","volume":"330","author":"J Abbasi","year":"2023","unstructured":"Abbasi J. FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. JAMA. 2023;330(22):2143\u20134.","journal-title":"JAMA"},{"key":"2263_CR27","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 08 Oct 2020."},{"issue":"3","key":"2263_CR28","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","volume":"51","author":"PE MacDonald","year":"2002","unstructured":"MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002;51(3):S434\u201342.","journal-title":"Diabetes"},{"issue":"3","key":"2263_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4093\/dmj.2023.0277","volume":"48","author":"T Bu","year":"2024","unstructured":"Bu T, Sun Z, Pan Y, Deng X, Yuan G. Glucagon-like peptide-1: new regulator in lipid metabolism. Diabetes Metab J. 2024;48(3):354\u201372. https:\/\/doi.org\/10.4093\/dmj.2023.0277.","journal-title":"Diabetes Metab J"},{"issue":"4","key":"2263_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s13300-023-01381-w","volume":"14","author":"K Heinla","year":"2023","unstructured":"Heinla K, Vasar E, Reppo I, Sedman T, Volke V. GLP-1 receptor agonists induce growth hormone secretion in healthy volunteers. Diabetes Ther. 2023;14(4):777\u201386. https:\/\/doi.org\/10.1007\/s13300-023-01381-w.","journal-title":"Diabetes Ther"},{"issue":"7","key":"2263_CR31","doi-asserted-by":"publisher","first-page":"R200","DOI":"10.1530\/EC-21-0130","volume":"10","author":"CR Andreasen","year":"2021","unstructured":"Andreasen CR, Andersen A, Knop FK, Vilsboll T. How glucagon-like peptide 1 receptor agonists work. Endocr Connect. 2021;10(7):R200\u201312.","journal-title":"Endocr Connect"},{"issue":"2","key":"2263_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/17460441.2013.741580","volume":"8","author":"DG Parkes","year":"2013","unstructured":"Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2013;8(2):219\u201344. https:\/\/doi.org\/10.1517\/17460441.2013.741580.","journal-title":"Expert Opin Drug Discov"},{"key":"2263_CR33","unstructured":"Helfand, C. GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn\u2019t bode well for Sanofi, AstraZeneca: analyst. https:\/\/www.fiercepharma.com\/marketing\/glaxosmithkline-glp-1-tanzeum-meets-its-end-and-it-doesn-t-bode-well-forsanofi-az. Accessed 12 June 2025. [cited]."},{"key":"2263_CR34","unstructured":"Tanzeum\u00ae (albiglutide)\u2014Drug discontinuation. https:\/\/professionals.optumrx.com\/publications\/library\/drugwithdrawal-tanzeum-2017-0726.html. Accessed 12 June 2025. [cited]."},{"issue":"6","key":"2263_CR35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","volume":"5","author":"R Nogueiras","year":"2023","unstructured":"Nogueiras R, Nauck MA, Tschop MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023;5(6):933\u201344. https:\/\/doi.org\/10.1038\/s42255-023-00812-z.","journal-title":"Nat Metab"},{"key":"2263_CR36","doi-asserted-by":"crossref","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","DOI":"10.1056\/NEJMoa2416394"},{"issue":"9","key":"2263_CR37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056\u201364.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2263_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10","key":"2263_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2263_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s13300-023-01520-3","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, Wang S, Wang Y, Luan J. Glycemic control, weight management, cardiovascular safety, and cost-effectiveness of semaglutide for patients with type 2 diabetes mellitus: a rapid review and meta-analysis of real-world studies. Diabetes Ther. 2024;15(2):497\u2013519. https:\/\/doi.org\/10.1007\/s13300-023-01520-3.","journal-title":"Diabetes Ther"},{"issue":"24","key":"2263_CR41","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882\u201394.","journal-title":"Circulation"},{"issue":"10402","key":"2263_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"10403","key":"2263_CR43","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705\u201319.","journal-title":"Lancet"},{"issue":"10403","key":"2263_CR44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","volume":"402","author":"VR Aroda","year":"2023","unstructured":"Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25\u00a0mg and 50\u00a0mg compared with 14\u00a0mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693\u2013704.","journal-title":"Lancet"},{"issue":"4","key":"2263_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2263_CR46","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2263_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"2","key":"2263_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"24","key":"2263_CR49","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"20","key":"2263_CR50","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"9","key":"2263_CR51","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/dom.14776","volume":"24","author":"D Yuan","year":"2022","unstructured":"Yuan D, Sharma H, Krishnan A, Vangaveti VN, Malabu UH. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2022;24(9):1869\u201381. https:\/\/doi.org\/10.1111\/dom.14776.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2263_CR52","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025;48(5):846\u201359.","journal-title":"Diabetes Care"},{"issue":"13","key":"2263_CR53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2263_CR54","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"23","key":"2263_CR55","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"10","key":"2263_CR56","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"1","key":"2263_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","volume":"18","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Bain SC, Hramiak I, Jodar E, Madsbad S, Gondolf T, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"2263_CR58","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.118.036862","volume":"138","author":"S Verma","year":"2018","unstructured":"Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, et al. Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use. Circulation. 2018;138(15):1605\u20137.","journal-title":"Circulation"},{"issue":"12","key":"2263_CR59","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","volume":"22","author":"S Verma","year":"2020","unstructured":"Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487\u201392. https:\/\/doi.org\/10.1111\/dom.14160.","journal-title":"Diabetes Obes Metab"},{"issue":"31","key":"2263_CR60","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/eurheartj\/ehab530","volume":"43","author":"K Oyama","year":"2022","unstructured":"Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J. 2022;43(31):2958\u201367.","journal-title":"Eur Heart J"},{"issue":"15","key":"2263_CR61","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"12","key":"2263_CR62","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","volume":"142","author":"MS Khan","year":"2020","unstructured":"Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation. 2020;142(12):1205\u201318.","journal-title":"Circulation"},{"issue":"10456","key":"2263_CR63","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(24)01763-X","volume":"404","author":"C Hage","year":"2024","unstructured":"Hage C. GLP-1 receptor agonists in heart failure: how far to expand use? Lancet. 2024;404(10456):909\u201311.","journal-title":"Lancet"},{"issue":"1","key":"2263_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2263_CR65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500\u20138.","journal-title":"JAMA"},{"issue":"12","key":"2263_CR66","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"18","key":"2263_CR67","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(18):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"7","key":"2263_CR68","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(7):949\u201361.","journal-title":"Lancet"},{"issue":"1","key":"2263_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2015.07.015.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2263_CR70","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11606-021-07105-9","volume":"37","author":"JT Alexander","year":"2022","unstructured":"Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, et al. The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. J Gen Intern Med. 2022;37(2):415\u201338. https:\/\/doi.org\/10.1007\/s11606-021-07105-9.","journal-title":"J Gen Intern Med"},{"key":"2263_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.910256","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Wang R, Ye H, Wang Y, Wang L, Zhang X. Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:910256. https:\/\/doi.org\/10.3389\/fendo.2022.910256.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2263_CR72","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181\u2013206."},{"key":"2263_CR73","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","DOI":"10.2337\/dci22-0034"},{"issue":"5","key":"2263_CR74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm\u20142023 update. Endocr Pract. 2023;29(5):305\u201340. https:\/\/doi.org\/10.1016\/j.eprac.2023.02.001.","journal-title":"Endocr Pract"},{"issue":"14","key":"2263_CR75","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(14):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"10","key":"2263_CR76","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","volume":"79","author":"MD Kelsey","year":"2022","unstructured":"Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison. J Am Coll Cardiol. 2022;79(10):1849\u201357.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2263_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126769","volume":"10","author":"JE Potts","year":"2015","unstructured":"Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS ONE. 2015;10(6):e0126769. https:\/\/doi.org\/10.1371\/journal.pone.0126769.","journal-title":"PLoS ONE"},{"issue":"7","key":"2263_CR78","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(7):1606\u201316.","journal-title":"Lancet"},{"issue":"6","key":"2263_CR79","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1021\/acsptsci.9b00048","volume":"2","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB. Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity. ACS Pharmacol Transl Sci. 2019;2(6):468\u201384.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"2263_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"2263_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.","journal-title":"Mol Metab"},{"issue":"11","key":"2263_CR82","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"14","key":"2263_CR83","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"2263_CR84","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10278","key":"2263_CR85","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"9","key":"2263_CR86","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","volume":"29","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29(9):2358\u201365.","journal-title":"Nat Med"},{"issue":"3","key":"2263_CR87","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"2263_CR88","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"1","key":"2263_CR89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"key":"2263_CR90","doi-asserted-by":"crossref","unstructured":"German J, Cordioli M, Tozzo V, Urbut S, Arumae K, Smit RAJ, et al. Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery. Nat Med. 2025;31(7):2269\u201376.","DOI":"10.1038\/s41591-025-03645-3"},{"issue":"4","key":"2263_CR91","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40261-024-01354-2","volume":"44","author":"X Tan","year":"2024","unstructured":"Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, et al. Real-world effectiveness of once-weekly glucagon-like peptide-1 receptor agonists (OW GLP-1RAs) in comparison with dipeptidyl peptidase-4 inhibitors (DPP-4is) for glycemic control and weight outcomes in type 2 diabetes mellitus (RELATE). Clin Drug Investig. 2024;44(4):271\u201384.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"2263_CR92","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41574-025-01160-6","volume":"21","author":"F Sanchis-Gomar","year":"2025","unstructured":"Sanchis-Gomar F, Neeland IJ, Lavie CJ. Balancing weight and muscle loss in GLP1 receptor agonist therapy. Nat Rev Endocrinol. 2025;21(10):584\u20135. https:\/\/doi.org\/10.1038\/s41574-025-01160-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2263_CR93","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","volume":"25","author":"A Bikou","year":"2024","unstructured":"Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024;25(5):611\u20139. https:\/\/doi.org\/10.1080\/14656566.2024.2343092.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"2263_CR94","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720\u20139. https:\/\/doi.org\/10.1111\/dom.16275.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2263_CR95","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473\u201385. https:\/\/doi.org\/10.1007\/s00125-019-05065-8.","journal-title":"Diabetologia"},{"key":"2263_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1240263","volume":"14","author":"S Volpe","year":"2023","unstructured":"Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Lavarra V, et al. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Front Endocrinol (Lausanne). 2023;14:1240263. https:\/\/doi.org\/10.3389\/fendo.2023.1240263.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2263_CR97","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jcsm.13445","volume":"15","author":"A Pandey","year":"2024","unstructured":"Pandey A, Patel KV, Segar MW, Ayers C, Linge J, Leinhard OD, et al. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial. J Cachexia Sarcopenia Muscle. 2024;15(3):1072\u201383. https:\/\/doi.org\/10.1002\/jcsm.13445.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2263_CR98","doi-asserted-by":"crossref","unstructured":"Zhygalina-Hritsenyuk M. The problem of sarcopenia in patients with obesity undergoing liraglutide therapy. In: Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025, Copenhagen, Denmark: Endocrine Abstracts; 2025.","DOI":"10.1530\/endoabs.110.EP898"},{"issue":"2","key":"2263_CR99","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cid\/ciae384","volume":"80","author":"GL Ditzenberger","year":"2025","unstructured":"Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, et al. Effects of semaglutide on muscle structure and function in the SLIM LIVER study. Clin Infect Dis. 2025;80(2):389\u201396.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2263_CR100","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998\u20131004.","journal-title":"Diabetes Care"},{"key":"2263_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2263_CR102","doi-asserted-by":"crossref","unstructured":"Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health all of us cohort. Pharmaceuticals (Basel). 2024;17(2):199.","DOI":"10.3390\/ph17020199"},{"key":"2263_CR103","doi-asserted-by":"crossref","unstructured":"Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145.","DOI":"10.3390\/jcm12010145"},{"issue":"5","key":"2263_CR104","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","volume":"7","author":"D Do","year":"2024","unstructured":"Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw Open. 2024;7(5):e2413172.","journal-title":"JAMA Netw Open"},{"key":"2263_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1502050","volume":"15","author":"R Gao","year":"2024","unstructured":"Gao R, Li Y, Li A, Zhou P, Zong H, Li Y. Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs. Front Endocrinol (Lausanne). 2024;15:1502050. https:\/\/doi.org\/10.3389\/fendo.2024.1502050.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2263_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1098032","volume":"14","author":"H Wu","year":"2023","unstructured":"Wu H, Lu Z, Chen R, Cai Q, Wang M, Zhang L, et al. Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes. Front Endocrinol (Lausanne). 2023;14:1098032. https:\/\/doi.org\/10.3389\/fendo.2023.1098032.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2263_CR107","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336\u201347.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2263_CR108","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.diabres.2015.04.009","volume":"109","author":"KY Thong","year":"2015","unstructured":"Thong KY, Gupta PS, Blann AD, Ryder RE. The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes. Diabetes Res Clin Pract. 2015;109(1):124\u20139. https:\/\/doi.org\/10.1016\/j.diabres.2015.04.009.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2263_CR109","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/dc23-1791","volume":"47","author":"KR Klein","year":"2024","unstructured":"Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of gastrointestinal adverse events upon GLP-1 receptor agonist initiation with concomitant metformin use: a post hoc analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. 2024;47(2):280\u20134.","journal-title":"Diabetes Care"},{"issue":"5","key":"2263_CR110","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139.","journal-title":"JAMA Intern Med"},{"key":"2263_CR111","doi-asserted-by":"crossref","unstructured":"Chiang CH, Jaroenlapnopparat A, Colak SC, Yu CC, Xanthavanij N, Wang TH, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology. 2025;169(6):1268\u201381.","DOI":"10.1053\/j.gastro.2025.06.003"},{"issue":"10","key":"2263_CR112","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","volume":"42","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB, Investigators LPCobotLT. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019;42(10):1912\u201320.","journal-title":"Diabetes Care"},{"issue":"10","key":"2263_CR113","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","volume":"176","author":"JL Faillie","year":"2016","unstructured":"Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474\u201381.","journal-title":"JAMA Intern Med"},{"key":"2263_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"Moll H, Frey E, Gerber P, Geidl B, Kaufmann M, Braun J, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024;73:102661. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102661.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2263_CR115","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamainternmed.2022.3810","volume":"182","author":"D Woronow","year":"2022","unstructured":"Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US food and drug administration. JAMA Intern Med. 2022;182(10):1104\u20136.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2263_CR116","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/cpt.2430","volume":"111","author":"JL Faillie","year":"2022","unstructured":"Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, et al. Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes. Clin Pharmacol Ther. 2022;111(1):272\u201382. https:\/\/doi.org\/10.1002\/cpt.2430.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2263_CR117","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","volume":"22","author":"P Ueda","year":"2024","unstructured":"Ueda P, Wintzell V, Melbye M, Eliasson B, Soderling J, Gudbjornsdottir S, et al. Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: scandinavian cohort study. Clin Gastroenterol Hepatol. 2024;22(6):1226-37 e14.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2263_CR118","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.7326\/ANNALS-24-03420","volume":"178","author":"Y Noh","year":"2025","unstructured":"Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L. Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes\u202f: a population-based cohort study. Ann Intern Med. 2025;178(9):1268\u201378. https:\/\/doi.org\/10.7326\/ANNALS-24-03420.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2263_CR119","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/gutjnl-2023-329651","volume":"73","author":"BD Liu","year":"2024","unstructured":"Liu BD, Udemba SC, Liang K, Tarabichi Y, Hill H, Fass R, et al. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut. 2024;73(2):246\u201354.","journal-title":"Gut"},{"issue":"1","key":"2263_CR120","doi-asserted-by":"publisher","first-page":"G26","DOI":"10.1152\/ajpgi.00293.2015","volume":"310","author":"Y Hou","year":"2016","unstructured":"Hou Y, Ernst SA, Heidenreich K, Williams JA. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am J Physiol Gastrointest Liver Physiol. 2016;310(1):G26-33.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"2263_CR121","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2337\/dc16-2684","volume":"40","author":"WM Steinberg","year":"2017","unstructured":"Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017;40(7):839\u201348. https:\/\/doi.org\/10.2337\/dc16-2684.","journal-title":"Diabetes Care"},{"issue":"4","key":"2263_CR122","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.13924","volume":"22","author":"M Abd El Aziz","year":"2020","unstructured":"Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22(4):699\u2013704.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2263_CR123","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2337\/dc16-0984","volume":"40","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Frossard JL, Barkin JS, Anglin G, Hensley IE, Harper KD, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647\u201354. https:\/\/doi.org\/10.2337\/dc16-0984.","journal-title":"Diabetes Care"},{"issue":"10","key":"2263_CR124","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jamainternmed.2016.1522","volume":"176","author":"L Azoulay","year":"2016","unstructured":"Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med. 2016;176(10):1464\u201373.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2263_CR125","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/10600280231205490","volume":"58","author":"K Wilhite","year":"2024","unstructured":"Wilhite K, Reid JM, Lane M. Risk of pancreatitis with incretin therapies versus thiazolidinediones in the veterans health administration. Ann Pharmacother. 2024;58(7):685\u20139. https:\/\/doi.org\/10.1177\/10600280231205490.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2263_CR126","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","volume":"68","author":"C Cao","year":"2020","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020;68(3):518\u201325. https:\/\/doi.org\/10.1007\/s12020-020-02223-6.","journal-title":"Endocrine"},{"issue":"2","key":"2263_CR127","doi-asserted-by":"publisher","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","volume":"48","author":"B Nreu","year":"2023","unstructured":"Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2023;48(2):206\u201313. https:\/\/doi.org\/10.23736\/S2724-6507.20.03219-8.","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"2263_CR128","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"issue":"1","key":"2263_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38956-2","volume":"9","author":"LC Pinto","year":"2019","unstructured":"Pinto LC, Falcetta MR, Rados DV, Leitao CB, Gross JL. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Sci Rep. 2019;9(1):2375.","journal-title":"Sci Rep"},{"key":"2263_CR130","doi-asserted-by":"crossref","unstructured":"Ayoub M, Faris C, Juranovic T, Chela H, Daglilar E. The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study. Cancers (Basel). 2024;16(9):1625.","DOI":"10.3390\/cancers16091625"},{"issue":"1","key":"2263_CR131","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4093\/dmj.2024.0105","volume":"49","author":"M Kim","year":"2025","unstructured":"Kim M, Kim SC, Kim J, Kim BH. Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus. Diabetes Metab J. 2025;49(1):49\u201359. https:\/\/doi.org\/10.4093\/dmj.2024.0105.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"2263_CR132","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024;7(1):e2350408.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2263_CR133","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/dmrr.1202","volume":"27","author":"VR Aroda","year":"2011","unstructured":"Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528\u201342. https:\/\/doi.org\/10.1002\/dmrr.1202.","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"2263_CR134","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMp1001578","volume":"362","author":"M Parks","year":"2010","unstructured":"Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide\u2014the FDA\u2019s review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"2263_CR135","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1753-0407.2010.00079.x","volume":"2","author":"Z Bloomgarden","year":"2010","unstructured":"Bloomgarden Z. Liraglutide and calcitonin. J Diabetes. 2010;2(4):223\u20134. https:\/\/doi.org\/10.1111\/j.1753-0407.2010.00079.x.","journal-title":"J Diabetes"},{"issue":"2","key":"2263_CR136","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0192623312472402","volume":"41","author":"TJ Rosol","year":"2013","unstructured":"Rosol TJ. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicol Pathol. 2013;41(2):303\u20139.","journal-title":"Toxicol Pathol"},{"issue":"4","key":"2263_CR137","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473\u201386. https:\/\/doi.org\/10.1210\/en.2009-1272.","journal-title":"Endocrinology"},{"issue":"1","key":"2263_CR138","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/jc.2011-2407","volume":"97","author":"B Gier","year":"2012","unstructured":"Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121\u201331. https:\/\/doi.org\/10.1210\/jc.2011-2407.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2263_CR139","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA, Monami M, Gallo M, Ragni A, Prattichizzo F, Renzelli V, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(3):891\u2013900.","journal-title":"Diabetes Obes Metab"},{"key":"2263_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859","volume":"13","author":"W Hu","year":"2022","unstructured":"Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:927859. https:\/\/doi.org\/10.3389\/fendo.2022.927859.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2263_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078225","volume":"385","author":"B Pasternak","year":"2024","unstructured":"Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjornsdottir S, Jonasson C, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225.","journal-title":"BMJ"},{"issue":"1","key":"2263_CR142","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/thy.2024.0387","volume":"35","author":"SM Baxter","year":"2025","unstructured":"Baxter SM, Lund LC, Andersen JH, Brix TH, Hegedus L, Hsieh MH, et al. Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study. Thyroid. 2025;35(1):69\u201378. https:\/\/doi.org\/10.1089\/thy.2024.0387.","journal-title":"Thyroid"},{"issue":"2","key":"2263_CR143","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384\u201390.","journal-title":"Diabetes Care"},{"issue":"2","key":"2263_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70038","volume":"8","author":"C Abi Zeid Daou","year":"2025","unstructured":"Abi Zeid Daou C, Aboul Hosn O, Ghzayel L, Mourad M. Exploring connections between weight-loss medications and thyroid cancer: a look at the FDA adverse event reporting system database. Endocrinol Diabetes Metab. 2025;8(2):e70038.","journal-title":"Endocrinol Diabetes Metab"},{"key":"2263_CR145","doi-asserted-by":"crossref","unstructured":"Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874\u201386.","DOI":"10.1001\/archopht.116.7.874"},{"issue":"6471","key":"2263_CR146","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/bmj.290.6471.811","volume":"290","author":"K Dahl-Jorgensen","year":"1985","unstructured":"Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811\u20135.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"9","key":"2263_CR147","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"2263_CR148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40261-021-01110-w","volume":"42","author":"F Wang","year":"2022","unstructured":"Wang F, Mao Y, Wang H, Liu Y, Huang P. Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2022;42(1):17\u201328. https:\/\/doi.org\/10.1007\/s40261-021-01110-w.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2263_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04096-7","volume":"25","author":"T Zhao","year":"2025","unstructured":"Zhao T, Zheng L, Feng Y, Lao M, Huang Y, Wu G. Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting. BMC Ophthalmol. 2025;25(1):248.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"2263_CR150","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17446651.2025.2459720","volume":"20","author":"H Singh","year":"2025","unstructured":"Singh H, Natt NK, Nim DK. Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data. Expert Rev Endocrinol Metab. 2025;20(2):147\u201352. https:\/\/doi.org\/10.1080\/17446651.2025.2459720.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2263_CR151","unstructured":"Research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03811561. Accessed 04 Sept 2023. [cited]."},{"issue":"8","key":"2263_CR152","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr., et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2263_CR153","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.orcp.2025.01.011","volume":"19","author":"M Azab","year":"2025","unstructured":"Azab M, Pasina L. Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system\u2014a disproportionality analysis. Obes Res Clin Pract. 2025;19(1):77\u20139.","journal-title":"Obes Res Clin Pract"},{"issue":"8","key":"2263_CR154","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327","volume":"8","author":"L Wang","year":"2025","unstructured":"Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2263_CR155","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","volume":"132","author":"CC Chou","year":"2025","unstructured":"Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, et al. Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study. Ophthalmology. 2025;132(4):381\u20138.","journal-title":"Ophthalmology"},{"issue":"2","key":"2263_CR156","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00041327-200306000-00012","volume":"23","author":"AC Arnold","year":"2003","unstructured":"Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23(2):157\u201363.","journal-title":"J Neuroophthalmol"},{"key":"2263_CR157","unstructured":"European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (June 2025). https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy? Accessed 29 Oct 2025."},{"issue":"3\u20134","key":"2263_CR158","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3\u20134):202\u201330.","journal-title":"Rev Diabet Stud"},{"issue":"3","key":"2263_CR159","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s13300-016-0187-6","volume":"7","author":"S Gentile","year":"2016","unstructured":"Gentile S, Strollo F, Ceriello A, Group A-OITS. Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear? Diabetes Ther. 2016;7(3):401\u20139.","journal-title":"Diabetes Ther"},{"issue":"9","key":"2263_CR160","volume":"15","author":"J Mizumoto","year":"2023","unstructured":"Mizumoto J. Tirzepatide-induced injection site reaction. Cureus. 2023;15(9):e45181.","journal-title":"Cureus"},{"issue":"3","key":"2263_CR161","doi-asserted-by":"publisher","first-page":"498","DOI":"10.2337\/dc12-0709","volume":"36","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes. Diabetes Care. 2013;36(3):498\u2013504. https:\/\/doi.org\/10.2337\/dc12-0709.","journal-title":"Diabetes Care"},{"key":"2263_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2263_CR163","doi-asserted-by":"crossref","unstructured":"Triplitt C, Chiquette E. Exenatide: from the Gila monster to the pharmacy. J Am Pharm Assoc (2003). 2006;46(1):44\u201352; quiz 3\u20135.","DOI":"10.1331\/154434506775268698"},{"key":"2263_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1032199","volume":"13","author":"S Dong","year":"2022","unstructured":"Dong S, Sun C. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Front Endocrinol (Lausanne). 2022;13:1032199.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2263_CR165","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.xkme.2020.10.008","volume":"3","author":"DJ Leehey","year":"2021","unstructured":"Leehey DJ, Rahman MA, Borys E, Picken MM, Clise CE. Acute kidney injury associated with semaglutide. Kidney Med. 2021;3(2):282\u20135.","journal-title":"Kidney Med"},{"issue":"4","key":"2263_CR166","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.xkme.2021.02.014","volume":"3","author":"D Patoulias","year":"2021","unstructured":"Patoulias D, Boulmpou A, Papadopoulos CE, Doumas M. Glucagon-like peptide-1 receptor agonists and the risk of acute kidney injury: alarming, or not? Kidney Med. 2021;3(4):674\u20135.","journal-title":"Kidney Med"},{"key":"2263_CR167","doi-asserted-by":"publisher","unstructured":"Kanduri SR, Kovacic R, Skipper GR, Velez JCQ. Exposure to glucagon-like peptide 1 receptor agonists does not increase the risk of AKI associated with anticancer therapy: FR-OR80. J Am Soc Nephrol. 2024;35(10S). https:\/\/doi.org\/10.1681\/ASN.2024x8y8t8d2.","DOI":"10.1681\/ASN.2024x8y8t8d2"},{"issue":"1","key":"2263_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50199-y","volume":"15","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT. GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024;15(1):5912.","journal-title":"Nat Commun"},{"issue":"3","key":"2263_CR169","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40620-022-01505-8","volume":"36","author":"J Alkas","year":"2023","unstructured":"Alkas J, Bosi A, Sjolander A, Barany P, Elinder CG, Fu EL. Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project. J Nephrol. 2023;36(3):705\u201311.","journal-title":"J Nephrol"},{"issue":"10295","key":"2263_CR170","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"10300","key":"2263_CR171","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"2263_CR172","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"key":"2263_CR173","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","volume":"14","author":"T Weiss","year":"2020","unstructured":"Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337\u201345.","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 2","key":"2263_CR174","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","volume":"27","author":"RW Thomsen","year":"2025","unstructured":"Thomsen RW, Mailhac A, Lohde JB, Pottegard A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(Suppl 2):66\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"2263_CR175","unstructured":"U.S. Food and Drug Administration. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type?. Accessed 3 Nov 2025."},{"issue":"11","key":"2263_CR176","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","volume":"184","author":"P Ueda","year":"2024","unstructured":"Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184(11):1301\u201312.","journal-title":"JAMA Intern Med"},{"key":"2263_CR177","doi-asserted-by":"crossref","unstructured":"Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, et al. Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European pharmacovigilance database. Pharmaceuticals (Basel). 2024;17(2):147.","DOI":"10.3390\/ph17020147"},{"issue":"8","key":"2263_CR178","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7326\/M24-0329","volume":"177","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Donahoo WT, Shao H, Shi L, Fonseca VA, et al. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes\u202f: a target trial emulation study. Ann Intern Med. 2024;177(8):1004\u201315.","journal-title":"Ann Intern Med"},{"key":"2263_CR179","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080679","volume":"388","author":"SB Shapiro","year":"2025","unstructured":"Shapiro SB, Yin H, Yu OHY, Rej S, Suissa S, Azoulay L. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. 2025;388:e080679.","journal-title":"BMJ"},{"issue":"1","key":"2263_CR180","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2042018814559725","volume":"6","author":"JM Trujillo","year":"2015","unstructured":"Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19\u201328. https:\/\/doi.org\/10.1177\/2042018814559725.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"2263_CR181","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317\u201332. https:\/\/doi.org\/10.1111\/dom.12596.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"2263_CR182","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","volume":"45","author":"J Trujillo","year":"2020","unstructured":"Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020;45(Suppl 1):43\u201360.","journal-title":"J Clin Pharm Ther"},{"key":"2263_CR183","doi-asserted-by":"publisher","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320. https:\/\/doi.org\/10.1177\/2042018821997320.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"2263_CR184","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524\u201336. https:\/\/doi.org\/10.1111\/dom.12849.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2263_CR185","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1463-1326.2012.01639.x","volume":"14","author":"T Ridge","year":"2012","unstructured":"Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(12):1097\u2013103. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01639.x.","journal-title":"Diabetes Obes Metab"},{"key":"2263_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, Chen Y, Zhou X, Liu S, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1149328. https:\/\/doi.org\/10.3389\/fendo.2023.1149328.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2263_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108737","volume":"174","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737. https:\/\/doi.org\/10.1016\/j.diabres.2021.108737.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2263_CR188","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"3","key":"2263_CR189","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.1002\/ajh.25381","volume":"94","author":"Y Vallatharasu","year":"2019","unstructured":"Vallatharasu Y, Hayashi-Tanner Y, Polewski PJ, Bottner WA, Rosenstein LJ, Uprety D, et al. Severe, prolonged thrombocytopenia in a patient sensitive to exenatide. Am J Hematol. 2019;94(3):E78\u201380. https:\/\/doi.org\/10.1002\/ajh.25381.","journal-title":"Am J Hematol"},{"issue":"4","key":"2263_CR190","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/ajh.26482","volume":"97","author":"S Nusrat","year":"2022","unstructured":"Nusrat S, Borogovac A, George JN, Curtis BR, Reese JA. Drug (vaccine)-induced thrombocytopenia 2021: diversity of pathogenesis and clinical features. Am J Hematol. 2022;97(4):E162\u20135. https:\/\/doi.org\/10.1002\/ajh.26482.","journal-title":"Am J Hematol"},{"key":"2263_CR191","unstructured":"Latif W, Lambrinos KJ, Patel P, et al. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs) [Updated 2024 Feb 25]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572151\/."},{"issue":"4","key":"2263_CR192","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70021","volume":"136","author":"L Kolding","year":"2025","unstructured":"Kolding L, Henriksen JN, Saedder EA, Ovesen PG, Pedersen LH. Pregnancy outcomes after Semaglutide exposure. Basic Clin Pharmacol Toxicol. 2025;136(4):e70021.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"2263_CR193","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1111\/dom.16437","volume":"27","author":"CH Parker","year":"2025","unstructured":"Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists\u2019 use during pregnancy: safety data from regulatory clinical trials. Diabetes Obes Metab. 2025;27(8):4102\u20138. https:\/\/doi.org\/10.1111\/dom.16437.","journal-title":"Diabetes Obes Metab"},{"key":"2263_CR194","doi-asserted-by":"crossref","unstructured":"Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024;16(17):2886.","DOI":"10.3390\/nu16172886"},{"key":"2263_CR195","unstructured":"Drugs and Lactation Database (LactMed\u00ae) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006. Semaglutide. [Updated 2024 Dec 15]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500980\/?."},{"key":"2263_CR196","doi-asserted-by":"crossref","unstructured":"Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.","DOI":"10.1542\/peds.2022-060640"},{"key":"2263_CR197","doi-asserted-by":"crossref","unstructured":"Liu L, Shi H, Shi Y, Wang A, Guo N, Tao H, et al. Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network meta-analysis. Pharmaceuticals (Basel). 2024;17(7):828.","DOI":"10.3390\/ph17070828"},{"key":"2263_CR198","doi-asserted-by":"crossref","unstructured":"Sedenho-Prado LG, Yugar LBT, Whitaker AR, Martins MP, Jesus DC, Ferreira I, et al. Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis. Int J Obes (Lond). 2025;49(8):1469-1479.","DOI":"10.1038\/s41366-025-01790-w"},{"issue":"5","key":"2263_CR199","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1345\/aph.1M676","volume":"44","author":"SL Anderson","year":"2010","unstructured":"Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010;44(5):904\u20139. https:\/\/doi.org\/10.1345\/aph.1M676.","journal-title":"Ann Pharmacother"},{"key":"2263_CR200","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283","volume":"4","author":"L Prasad-Reddy","year":"2015","unstructured":"Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. https:\/\/doi.org\/10.7573\/dic.212283.","journal-title":"Drugs Context"},{"issue":"18","key":"2263_CR201","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795\u20137.","journal-title":"JAMA"},{"issue":"4","key":"2263_CR202","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2337\/cd19-0100","volume":"38","author":"JP Almandoz","year":"2020","unstructured":"Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390\u2013402. https:\/\/doi.org\/10.2337\/cd19-0100.","journal-title":"Clin Diabetes"},{"issue":"3","key":"2263_CR203","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2337\/cd22-0020","volume":"40","author":"J Anderson","year":"2022","unstructured":"Anderson J, Gavin JR 3rd, Kruger DF, Miller E. Optimizing the use of glucagon-like peptide 1 receptor agonists in type 2 diabetes: executive summary. Clin Diabetes. 2022;40(3):265\u20139.","journal-title":"Clin Diabetes"},{"issue":"24","key":"2263_CR204","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","volume":"54","author":"FC Bull","year":"2020","unstructured":"Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451\u201362. https:\/\/doi.org\/10.1136\/bjsports-2020-102955.","journal-title":"Br J Sports Med"},{"issue":"12","key":"2263_CR205","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.mayocp.2024.07.007","volume":"99","author":"R Arena","year":"2024","unstructured":"Arena R, Pronk NP, Lavie CJ. Pharma-cise in the glucagon-like peptide-1 receptor agonists era: a concept whose time has come. Mayo Clin Proc. 2024;99(12):1869\u201373.","journal-title":"Mayo Clin Proc"},{"key":"2263_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102475","volume":"69","author":"SBK Jensen","year":"2024","unstructured":"Jensen SBK, Blond MB, Sandsdal RM, Olsen LM, Juhl CR, Lundgren JR, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClin Med. 2024;69:102475. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102475.","journal-title":"EClin Med"},{"issue":"1","key":"2263_CR207","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2263_CR208","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(21)00084-2","volume":"2","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB, et al. Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a\/b trial. Lancet Healthy Longev. 2021;2(5):e263\u201374.","journal-title":"Lancet Healthy Longev"},{"issue":"10","key":"2263_CR209","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20836","volume":"3","author":"D Rooks","year":"2020","unstructured":"Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N, et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open. 2020;3(10):e2020836.","journal-title":"JAMA Netw Open"},{"key":"2263_CR210","unstructured":"Heymsfield SB. Can we improve the quality of weight loss by augmenting fat mass loss while preserving lean mass? The BELIEVE study of bimagrumab\u00a0+\u00a0semaglutide. Chicago: American Diabetes Association 85th Scientific Sessions; 2025."},{"key":"2263_CR211","doi-asserted-by":"crossref","unstructured":"Gottlieb R. Continuous protein sensor for sarcopenia management during GLP-1 RA therapy. Chicago: American Diabetes Association 85th Scientific Sessions; 2025.","DOI":"10.2337\/db25-2041-LB"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02263-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02263-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02263-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:02:22Z","timestamp":1768359742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02263-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":211,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2263"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02263-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Setor K. Kunutsor: conceptualization, methodology, data curation, formal analysis, investigation, original draft, writing\u2014review and editing. Samuel Seidu: methodology, data curation, formal investigation, writing\u2014review and editing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"This is a narrative review; no new scientific data was generated, and all data are within the paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}